SCHEMBL20725319

SCHEMBL20725319

CC(C)n1[nH]c(=O)c2ccccccccccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.43
DAO P14920 2/20 0.41
POLB P06746 2/20 0.41
PARP1 P09874 2/20 0.39
PGR P06401 1/20 0.39
CYP1A2 P05177 1/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTT P42858 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
PLK1 P53350 1/20 0.37
LDHA P00338 1/20 0.37
LCK P06239 1/20 0.36
PRKACA P17612 1/20 0.36
CSNK2A2 P19784 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270985 0.98 TP53 (0.46) KDM4ETP53TSHRDAOPOLB
SCHEMBL30056795 0.98 TP53 (0.46) KDM4ETP53TSHRDAOPOLB
SCHEMBL3894139 0.82 SMN1; SMN2 (0.41) KDM4ETP53TSHRDAOPOLB
SCHEMBL30839913 0.75 KDM4E (0.45) KDM4ETP53TSHRDAOPARP1
SCHEMBL20916716 0.74 KDM4E (0.35) KDM4ETP53TSHRDAOPARP1
SCHEMBL29845563 0.74 KDM4E (0.64) KDM4ETP53TSHRDAOPARP1
SCHEMBL2270654 0.74 KDM4E (0.64) KDM4ETP53TSHRDAOPARP1
SCHEMBL4753544 0.73 CHRM2 (0.37) KDM4EPOLBPARP1ALDH1A1L3MBTL1
SCHEMBL22152272 0.73 MAT2A (0.38) KDM4ETP53ALDH1A1HTTGAA
SCHEMBL29261559 0.73 PARP1 (0.42) KDM4EPARP1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202353-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2019-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202353-B2 Therapeutic compounds RPL35, SARS1, HAVCR2 KDM4E 4403/4885TP53 1990/4885TSHR 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.